INS and type 2 diabetes mellitus: However, in 2019, a clinical Glucagon-like-peptide-1 (GLP-1) receptor agonist called Rybelsus® (Semaglutide) came into the market that treats Type 2 diabetes by stimulating the secretion of insulin from the pancreas [14].